Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte, Inc.

In a report released yesterday, from Guggenheim reiterated a Buy rating on Vaxcyte, with a price target of $116.00. The company’s shares closed yes...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PCVX	$60.03	+3.38%	214.37K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PCVX	$60.03	+3.4%	214.37K
3
4
5
6

PCVX

Get Vaxcyte, Inc. Data in Excel

Get Vaxcyte, Inc. Data in Excel